{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T20:07:59Z","timestamp":1795291679268,"version":"4.10.3"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>\n                    We used the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database to examine whether history of a solid\n                    <jats:italic toggle=\"yes\">versus<\/jats:italic>\n                    hematologic malignancy impacts outcomes after left ventricular assist device (LVAD) implantation. We included LVAD recipients (2007\u20132017) with cancer history reported (N = 14,799, 21% female, 24% Black). Multivariate models examined the association between cancer type and post-LVAD mortality and adverse events. Competing risk analyses compared death and heart transplantation between cancer types and those without cancer in bridge-to-transplant (BTT) patients. A total of 909 (6.1%) patients had a history of cancer (4.9% solid tumor, 1.3% hematologic malignancy). Solid tumors were associated with higher mortality (adjusted hazard ratio [aHR] = 1.31, 95% confidence interval [CI] = 1.09\u20131.57), major bleeding (aHR = 1.15, 95% CI = 1.00\u20131.32), and pump thrombosis (aHR = 1.52, 95% CI = 1.09\u20132.13), whereas hematologic malignancies were associated with increased major infection (aHR = 1.43, 95% CI = 1.14\u20131.80). Compared to BTT patients without a history of cancer, solid tumor patients were less likely to undergo transplantation (adjusted subdistribution HR [aSHR] = 0.63, 95% CI = 0.45\u20130.89) and hematologic malignancy patients were as likely to experience death (aSHR = 1.16, 95% CI = 0.63\u20132.14) and transplantation (aSHR = 0.69, 95% CI = 0.44\u20131.08). Cancer history and type impact post-LVAD outcomes. As LVAD utilization in cancer survivors increases, we need strategies to improve post-LVAD outcomes in these patients.\n                  <\/jats:p>","DOI":"10.1097\/mat.0000000000002108","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T17:00:45Z","timestamp":1701450045000},"page":"272-279","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Associations Between Preimplant Cancer Type and Left Ventricular Assist Device Outcomes: An INTERMACS Registry Analysis"],"prefix":"10.1097","volume":"70","author":[{"given":"Rebecca S.","family":"Steinberg","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Nayak","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Okoh","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Matiello","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanna A.","family":"Morris","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Cowger","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Henry Ford Health, Detroit, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7113-1118","authenticated-orcid":false,"given":"Anju","family":"Nohria","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"R1-20250530","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaccao.2021.11.007","article-title":"Cancer incidence and mortality according to pre-existing heart failure in a community-based cohort.","volume":"4","author":"Bertero","year":"2022","journal-title":"JACC CardioOncol"},{"key":"R2-20250530","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jacc.2013.04.088","article-title":"Patients with heart failure have an increased risk of incident cancer.","volume":"62","author":"Hasin","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R3-20250530","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: Executive summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R4-20250530","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/AC.70.2.3073502","article-title":"Heart transplantation in patients with previous malignancy. An overview.","volume":"70","author":"Mistiaen","year":"2015","journal-title":"Acta Cardiol"},{"key":"R5-20250530","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.healun.2012.09.013","article-title":"The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: Executive summary.","volume":"32","author":"Feldman","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"R6-20250530","doi-asserted-by":"crossref","first-page":"e1145","DOI":"10.1161\/CIR.0000000000000507","article-title":"Recommendations for the use of mechanical circulatory support: Ambulatory and community patient care: A scientific statement from the American Heart Association.","volume":"135","author":"Cook","year":"2017","journal-title":"Circulation"},{"key":"R7-20250530","first-page":"1485","article-title":"Left ventricular assist device implantation in cancer-therapy-related heart failure.","volume":"12","author":"Mulzer","year":"2022","journal-title":"Life (Basel)"},{"key":"R8-20250530","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/jocs.14723","article-title":"Left ventricular assist device implantation in patients with a history of malignancy.","volume":"35","author":"Hong","year":"2020","journal-title":"J Card Surg"},{"key":"R9-20250530","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/clc.22672","article-title":"The influence of chemotherapy on the right ventricle: Did we forget something?","volume":"40","author":"Tadic","year":"2017","journal-title":"Clin Cardiol"},{"key":"R10-20250530","first-page":"e009772","article-title":"Characteristics and outcome of patients with a history of cancer undergoing durable left ventricular assist device implantation.","volume":"16","author":"Tie","year":"2022","journal-title":"Circ Heart Fail"},{"key":"R11-20250530","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jpainsymman.2017.08.030","article-title":"Comparing the palliative care needs of patients with hematologic and solid malignancies.","volume":"55","author":"Hochman","year":"2018","journal-title":"J Pain Symptom Manage"},{"key":"R12-20250530","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.hlc.2012.02.004","article-title":"Cardiac surgery in patients with a history of malignancy: Increased complication rate but similar mortality.","volume":"21","author":"Chan","year":"2012","journal-title":"Heart Lung Circ"},{"key":"R14-20250530","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.healun.2017.07.005","article-title":"Eighth annual INTERMACS report: Special focus on framing the impact of adverse events.","volume":"36","author":"Kirklin","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"R15-20250530","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.healun.2018.11.013","article-title":"The Society of Thoracic Surgeons Intermacs database annual report: Evolving indications, outcomes, and scientific partnerships.","volume":"38","author":"Kormos","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"R16-20250530","first-page":"247","article-title":"A population based analysis of trends, risk factors and outcomes associated with gastrointestinal bleeding in patients with left ventricular assist devices.","volume":"10","author":"Gonuguntla","year":"2020","journal-title":"Am J Cardiovasc Dis"},{"key":"R17-20250530","doi-asserted-by":"crossref","first-page":"e002680","DOI":"10.1161\/CIRCHEARTFAILURE.115.002680","article-title":"Relationship between anticoagulation intensity and thrombotic or bleeding outcomes among outpatients with continuous-flow left ventricular assist devices.","volume":"9","author":"Nassif","year":"2016","journal-title":"Circ Heart Fail"},{"key":"R18-20250530","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.amjcard.2015.10.041","article-title":"Risk factors and outcomes of gastrointestinal bleeding in left ventricular assist device recipients.","volume":"117","author":"Joy","year":"2016","journal-title":"Am J Cardiol"},{"key":"R19-20250530","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1111\/jocs.16545","article-title":"Infectious complications following contemporary left ventricular assist device implantation.","volume":"37","author":"Zhu","year":"2022","journal-title":"J Card Surg"},{"key":"R20-20250530","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/jocs.13718","article-title":"Risk factors for stroke on left ventricular assist devices.","volume":"33","author":"Bishawi","year":"2018","journal-title":"J Card Surg"},{"key":"R21-20250530","doi-asserted-by":"crossref","first-page":"e008706","DOI":"10.1161\/CIRCHEARTFAILURE.121.008706","article-title":"Right heart failure following left ventricular device implantation: Natural history, risk factors, and outcomes: An analysis of the STS INTERMACS database.","volume":"15","author":"Kapelios","year":"2022","journal-title":"Circ Heart Fail"},{"key":"R22-20250530","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s11936-015-0388-8","article-title":"Management of advanced heart failure due to cancer therapy: The present role of mechanical circulatory support and cardiac transplantation.","volume":"17","author":"Deo","year":"2015","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"R23-20250530","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ejhf.1165","article-title":"Cancer diagnosis in patients with heart failure: Epidemiology, clinical implications and gaps in knowledge.","volume":"20","author":"Ameri","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"R24-20250530","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023.","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R25-20250530","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.athoracsur.2022.11.023","article-title":"The Society of Thoracic Surgeons Intermacs 2022 Annual Report: Focus on the 2018 Heart Transplant Allocation System.","volume":"115","author":"Yuzefpolskaya","year":"2023","journal-title":"Ann Thorac Surg"},{"key":"R26-20250530","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.healun.2012.09.007","article-title":"Long-term follow-up of lung and heart transplant recipients with pre-transplant malignancies.","volume":"31","author":"Sigurdardottir","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"R27-20250530","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1002\/ehf2.13362","article-title":"Outcomes in patients with anthracycline-induced cardiomyopathy undergoing left ventricular assist devices implantation.","volume":"8","author":"Guha","year":"2021","journal-title":"ESC Heart Fail"},{"key":"R28-20250530","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jacc.2013.09.040","article-title":"Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: Outcomes from the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support).","volume":"63","author":"Oliveira","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R29-20250530","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.hfc.2016.12.005","article-title":"Advanced heart failure therapies for cancer therapeutics-related cardiac dysfunction.","volume":"13","author":"Bianco","year":"2017","journal-title":"Heart Fail Clin"},{"key":"R30-20250530","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/ajt.16318","article-title":"Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement.","volume":"21","author":"Al-Adra","year":"2021","journal-title":"Am J Transplant"},{"key":"R31-20250530","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.healun.2012.03.018","article-title":"Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation.","volume":"31","author":"Oliveira","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"R32-20250530","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.trre.2017.08.003","article-title":"Cancer recurrence after solid organ transplantation: A systematic review and meta-analysis.","volume":"31","author":"Acuna","year":"2017","journal-title":"Transplant Rev (Orlando)"},{"key":"R33-20250530","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis.","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"key":"R34-20250530","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.bjc.6605599","article-title":"Epidemiology and pathophysiology of cancer-associated thrombosis.","volume":"102","author":"Noble","year":"2010","journal-title":"Br J Cancer"},{"key":"R35-20250530","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0889-8588(18)30277-6","article-title":"Bleeding problems in the cancer patient.","volume":"6","author":"Rosen","year":"1992","journal-title":"Hematol Oncol Clin North Am"},{"key":"R36-20250530","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"key":"R37-20250530","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1182\/asheducation-2003.1.438","article-title":"Infections in patients with hematological cancer: Recent developments.","volume":"2003:","author":"O\u2019Brien","year":"2003","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R38-20250530","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3816\/CLM.2009.n.071","article-title":"Infectious complications in patients with chronic lymphocytic leukemia: Pathogenesis, spectrum of infection, and approaches to prophylaxis.","volume":"9","author":"Morrison","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"R39-20250530","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/jha2.338","article-title":"Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice.","volume":"3","author":"Sengsayadeth","year":"2022","journal-title":"EJHaem"},{"key":"R40-20250530","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/14787210.2021.1855143","article-title":"CAR-T cell therapy and infection: A review.","volume":"19","author":"Bupha-Intr","year":"2021","journal-title":"Expert Rev Anti Infect Ther"}],"container-title":["ASAIO Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MAT.0000000000002108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T09:00:20Z","timestamp":1748595620000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MAT.0000000000002108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mat.0000000000002108","relation":{},"ISSN":["1058-2916"],"issn-type":[{"value":"1058-2916","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}